Do HSP90 inhibitors induce autophagy?
Best insight from top research papers
HSP90 inhibitors have been shown to induce autophagy in multiple studies. DPB, a novel HSP90 inhibitor, was found to induce mTOR-independent autophagy in lung cancer cells . Another study identified DCZ5248 as a dual inhibitor of HSP90 and late-autophagy, which induced autophagy inhibition through impairment of lysosomal functions . Additionally, the combination of HSP90 inhibitor 17-AAG and autophagy inhibitor 3-MA was found to enhance apoptosis without enhanced autophagy, suggesting an antagonistic relationship between autophagy and apoptosis . Furthermore, the HSP90 inhibitor NVP-AUY922 was found to induce autophagic flux and enhance chaperone-mediated autophagy (CMA) activity, leading to the degradation of IGF-1Rβ protein in pancreatic cancer cells . These findings collectively suggest that HSP90 inhibitors can induce autophagy through various mechanisms.
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
16 Citations | The paper does not directly address whether HSP90 inhibitors induce autophagy. The paper focuses on a novel dual inhibitor, DCZ5248, which inhibits both HSP90 and autophagy and shows antitumor activity against colon cancer. |
| The paper states that the HSP90 inhibitor DPB induces mTOR-independent autophagy in A549 lung cancer cells. Therefore, HSP90 inhibitors can induce autophagy. | |
4 Citations | The paper does not directly mention whether HSP90 inhibitors induce autophagy. |
12 Citations | The paper states that the HSP90 inhibitor NVP-AUY922 induces autophagic flux by increasing LC3II expression and puncta formation. |
| The paper does not directly mention whether HSP90 inhibitors induce autophagy. |
Related Questions
Docking study on HSP90 inhibitor for neurogenerative disease5 answersDocking studies on HSP90 inhibitors for neurodegenerative diseases have shown promising results. HSP90 inhibitors like NXD30001, geldanamycin, and 19-phenyl-GA have demonstrated efficacy in inducing heat shock proteins (HSPs), reducing toxic protein aggregation, mitochondrial fragmentation, and neuronal death. Additionally, the cochaperone Aha1 has been implicated in promoting tau fibril formation and neurotoxicity through the Hsp90 system. These findings suggest that targeting HSP90 and its cochaperones could be a valuable strategy for mitigating protein misfolding and aggregation in neurodegenerative diseases like Alzheimer's and Parkinson's. Further research utilizing docking studies with HSP90 inhibitors may provide insights into their mechanisms of action and potential for therapeutic development in neurodegenerative disorders.
What drugs activate autophagy?5 answersVarious drugs have been identified to activate autophagy, offering potential therapeutic benefits. Herbal medicines contain components with anticancer effects, some of which induce autophagy as a potential cancer treatment. Phenothiazine derivatives, used in schizophrenia treatment, have been shown to modulate autophagy in vitro, impacting normal and cancer cell lines. ABTL0812, a small molecule under clinical evaluation for anti-cancer activity, induces cytotoxic autophagy by increasing cellular dihydroceramides, leading to ER stress and unfolded protein response activation. Autophagy plays a crucial role in various diseases, including cancer, and its dysregulation can be targeted by pharmacological inducers like rapamycin, which enhances autophagy to promote neuroprotection against protein misfolding-associated neurodegeneration. These findings highlight the diverse drug classes that can activate autophagy for potential therapeutic interventions.
Does inhibition of mTOR suppress autophagy?5 answersInhibition of mTOR has been shown to suppress autophagy. Studies have observed that inhibition of mTOR either genetically or pharmacologically leads to a decrease in autophagic processes. Additionally, the phosphorylation of mTOR, which indicates its activation, is reduced in patients with ischemic stroke. Furthermore, the activation of autophagy is increased by mTOR inhibition in glioma cells. These findings suggest that mTOR plays a positive regulatory role in autophagy, and its inhibition leads to a suppression of autophagic processes.
What is the clinical prospect of drugs targeting autophagy?4 answersDrugs targeting autophagy show promise in clinical use, although their effectiveness varies. Clinical trials using autophagy inhibitors, such as hydroxychloroquine (HCQ), have produced mixed results. However, more potent and specific autophagy inhibitors are being developed and tested in clinical trials. Autophagy induction has demonstrated significant improvement in organismal lifespan and pathology modulation in preclinical models of age-related neurodegenerative diseases. In the context of cancer, autophagy inhibition has been shown to enhance the efficacy of chemotherapy, targeted therapy, and immunotherapy. The role of autophagy in cancer and its potential as a therapeutic target is being explored in clinical trials. In the case of ER-positive breast cancer, the cytoprotective role of autophagy induced by endocrine therapies is being investigated, and further studies are needed to determine if autophagy inhibition can improve treatment outcomes. Overall, drugs targeting autophagy hold promise for clinical use, but further research is needed to optimize their effectiveness and identify the most suitable patient populations.
Do Hsp90 inhibitors have the potential to treat skin diseases?4 answersHsp90 inhibitors have the potential to treat skin diseases, including inflammatory skin diseases and blistering skin diseases. They have been suggested as a potential drug target in inflammatory skin diseases based on in vitro and in vivo studies in animal models and human clinical trials. In addition, Hsp90 inhibitors have been studied in vitro, ex vivo, and in vivo using animal models to understand their role in blistering skin diseases. Furthermore, topical treatment with an Hsp90 inhibitor has shown to prevent UVR-induced squamous cell carcinomas in mice. These findings suggest that Hsp90 inhibitors could be effective in treating skin diseases and preventing skin cancer.
Does Tylenol break autophagy?5 answers